Moderna, Inc. (MRNA)
After hours:
| Previous close | 132.06 |
| Open | 130.98 |
| Bid | 130.36 x 1200 |
| Ask | 130.90 x 1000 |
| Day's range | 126.29 - 133.00 |
| 52-week range | 119.01 - 497.49 |
| Volume | |
| Avg. volume | 6,887,137 |
| Market cap | 52.047B |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | 3.85 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Senti Bioscien
- GlobeNewswire
Leaders: Moderna, Tilray, PharmaDrug, and Vinco; Visionary CEO Highlight New Trends in Vaccines, Biotech, Digital Media, and Consumer Brands
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Moderna, Inc. (NASDAQ: MRNA), PharmaDrug (OTC: LMLLF) (CSE: PHRX) Tilray, Inc. (NASDAQ:TLRY) and Vinco Ventures (NASDAQ: BBIG). Today’s emerging technologies and lifestyle megatrends are unleashing trillion dollar market opportunities for disruptive innovation in how we live, work and play. Wall Street Reporter
- GlobeNewswire
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,
